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Sierro and colleagues1 have reported some important ﬁndings in
29 of 48 patients with post-traumatic nightmares who underwent a study to assess the long-term effects of imagery rehearsal
therapy (IRT) on nightmare frequency (NF), and completed
4-year follow-up questionnaires prior to the 17 March 2020
French coronavirus disease 2019 (COVID-19) lockdown. To
estimate IRT robustness, 23 of 29 patients also completed the
questionnaires at the end of the lockdown in May 2020. Some of
the salient ﬁndings from 20 of 23 patients were as follows: preIRT the mean (SD) monthly NF was 28.8 (20); post-IRT, 8.9
(8.9); at 4-year follow-up prior to the March lockdown, 6.25
(10.6); with a post-lockdown increase (P = .003) in NF to 19.35
(32). Overall, 13 of 20 (65%) reported an increased NF and 7
of 20 (35%) reported no lockdown effect. However, the postlockdown increase in mean NF was accounted for by only 2 of
20 patients who reported a greater than pre-IRT NF during
lockdown; the post-lockdown NF was 9.5 (10) after these 2
patients were excluded.1 The authors note that, for the treatment
responders (n = 18), during lockdown the NF remained 3 times
lower than pre-IRT levels.1 During lockdown, the nightmare
content was variable, with only 30% involving the original
trauma and 5% COVID-19.1 The signiﬁcant reduction in overall
post-traumatic stress disorder (PTSD) symptoms during IRT
was sustained over 4 years (P = .008).1 The authors comment on
the robustness of IRT effects to stress re-exposure and time.1
IRT is a nightmare-focused treatment, which uses a cognitivebehavioral model including mastery, where nightmares are
treated as learned behaviors that can be controlled by working on
them while awake.2 IRT not only improves nightmares and sleep
but also decreases overall PTSD symptoms (intrusion, avoidance, arousal).2 This was also noted by Sierro and colleagues1
who observed an essentially 3-fold decrease in the frequency
of traumatic nightmares and sustained improvement in global
PTSD symptoms 4 years post-IRT, including post-lockdown.
The robustness of the beneﬁcial effects of IRT likely represents
an overall decrease in the activation of the fear circuitry and improved emotional regulation with targeted treatment of nightmares.
Nightmares likely represent a primary feature of sympathetic activation in patients with PTSD, which can be a treatment target for
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PTSD. This is possibly further supported by the observation that
treatment of emergent nonspeciﬁc nightmares in patients with
PTSD (previously in remission) during the COVID-19 lockdown
with the α-adrenergic receptor blocking agent prazosin (which
reduces central sympathetic outﬂow) may have aided in the
prevention of a full PTSD relapse.3
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